CADTH | Evidence Driven
CADTH | Evidence Driven

Tecovirimat for the Treatment of Human Monkeypox

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HC0040-000

Tecovirimat is an oral antiviral therapy approved in Canada for the treatment of human smallpox disease in adult and pediatric patients weighing at least 13 kg. While tecovirimat is only approved for the treatment of smallpox, CADTH conducted a review of the evidence and convened an Implementation Advice Panel to prioritize the patient populations that are most likely to benefit from tecovirimat for the treatment of human monkeypox infection.

 

Files

Tecovirimat for the Treatment of Human Monkeypox: Updated report September 28, 2022 View PDF
Tecovirimat for the Treatment of Human Monkeypox: Original report July 12, 2022 View PDF
Last Updated : July 12, 2022